Amia Capital LLP Neurocrine Biosciences Inc Transaction History

Amia Capital LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$86.91 - $108.33 $1.39 Million - $1.73 Million	-15,939 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $226,937 - $318,954	-2,360 Reduced 12.9%	15,939 $1.53 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $837,285 - $1.28 Million	-9,840 Reduced 34.97%	18,299 $2.23 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $498,204 - $754,570	-6,633 Reduced 19.08%	28,139 $2.44 Million
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $3.02 Million - $4.12 Million	34,772 New	34,772 $3.74 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Amia Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Amia Capital LLP with notifications on news.